Literature DB >> 19800335

Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

Paola Fisicaro1, Caterina Valdatta, Marco Massari, Elisabetta Loggi, Elisabetta Biasini, Luca Sacchelli, Maria Cristina Cavallo, Enrico M Silini, Pietro Andreone, Gabriele Missale, Carlo Ferrari.   

Abstract

BACKGROUND & AIMS: The antiviral function of peripheral hepatitis B virus (HBV)-specific T cells can be increased in patients with chronic hepatitis B by blocking the interaction of programmed death (PD)-1 with its ligand PD-L1. However, no information is available about the effects of this blockade on intrahepatic lymphocytes. We studied T-cell exhaustion and the effects of PD-1/PD-L1 blockade on intrahepatic and circulating HBV-specific T cells in patients with chronic hepatitis B.
METHODS: A total of 42 patients with chronic HBV infection who underwent liver biopsy were studied. The ex vivo phenotype of peripheral and intrahepatic HBV-specific CD8(+) T cells was assessed by flow cytometry with class I tetramers and antibodies to T-cell differentiation molecules. Functional recovery was evaluated by analyzing expansion and production of interferon (IFN)-gamma and interleukin (IL)-2 after short-term incubation of T cells with HBV peptides in the presence of anti-PD-L1 or control antibodies.
RESULTS: Intrahepatic HBV-specific CD8(+) cells expressed higher levels of PD-1 and lower levels of CD127 than their peripheral counterparts. Blockade of PD-1/PD-L1 interaction increased CD8(+) cell proliferation and IFN-gamma and IL-2 production by circulating intrahepatic lymphocytes, even though anti-PD-L1 had a stronger effect on intrahepatic compared with peripheral T cells.
CONCLUSIONS: T-cell exhaustion by high antigen concentrations promotes HBV-specific T-cell dysfunction by affecting phenotype and function of peripheral and intrahepatic T cells. By restoring antiviral T-cell functions, not only in peripheral but also in intrahepatic lymphocytes, anti-PD-L1 might be a good therapeutic candidate for chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800335     DOI: 10.1053/j.gastro.2009.09.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  169 in total

Review 1.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

2.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

Review 3.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

4.  Balance lost: T cell immunity in progressive HBV infection.

Authors:  Bertram Bengsch; Robert Thimme
Journal:  Hepatol Int       Date:  2014-01-09       Impact factor: 6.047

Review 5.  Immune therapy for hepatitis B.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Md Sakilur Islam Khan; Ruksana Raihan; Ananta Shrestha
Journal:  Ann Transl Med       Date:  2016-09

6.  Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.

Authors:  Yuichiro Shindo; Jacqueline Unsinger; Cary-Ann Burnham; Jonathan M Green; Richard S Hotchkiss
Journal:  Shock       Date:  2015-04       Impact factor: 3.454

7.  Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.

Authors:  Amy C Sherman; Nirupama Trehanpati; Marybeth Daucher; Richard T Davey; Henry Masur; Shiv Kumar Sarin; Shyam Kottilil; Anita Kohli
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-11       Impact factor: 2.205

Review 8.  Eradication Strategies for Chronic Hepatitis B Infection.

Authors:  Eleanor M P Wilson; Lydia Tang; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

9.  B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function.

Authors:  Gang Cai; Xiaomeng Nie; Lei Li; Liang Hu; Beiying Wu; Jiafei Lin; Cen Jiang; Huaizhou Wang; Xuefeng Wang; Qian Shen
Journal:  J Gastroenterol       Date:  2013-03-27       Impact factor: 7.527

Review 10.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.